Drug Discovery

Drug discovery is an intricate process filled with complexity at every turn. Understanding disease mechanisms, identifying therapeutic targets, and developing effective treatments requires cutting-edge technology capable of capturing a holistic view. Multi-omics services combining next-generation sequencing (NGS) and mass spectrometry provide the high-resolution insights needed to accelerate drug discovery and development. By elucidating genomic, transcriptomic, proteomic and metabolomic profiles, our multi-omics solutions shed light on the interconnected biology underlying disease and response to therapy. With an in-depth perspective spanning DNA to RNA to protein, our services equip researchers to overcome complexity, enhancing the discovery of biomarkers, validating targets, and predicting patient outcomes along the drug development pipeline.

Home

/Drug Discovery

Multi-omics in Drug Discovery

Comprehensive NGS and proteomics unravel disease mechanisms by identifying aberrant genes, pathways, and protein interactions to spotlight promising therapeutic targets.

Multi-omics analysis detects genomic, transcriptomic and proteomic biomarkers to enable patient stratification, predict treatment response, and track disease progression.

Integrated omics data validates drug target relevancy by connecting expression patterns and functional impact to disease pathology.

Combining NGS, proteomics and metabolomics maps gene-protein-metabolite networks to predict patient-specific drug responses.

Proteomics can be used to screen drug targets and evaluate drug efficacy, accelerating the drug development process.

Metabolomics can be used to study drug metabolism and drug mechanisms of action, and by analyzing metabolic data, discover new drug targets and metabolic markers, providing more clues and evidence for drug development and evaluation.

Biologics are medications that are prescribed to treat illnesses such as cancer, rheumatoid arthritis, and multiple sclerosis. By characterizing biologics, researchers can improve their effectiveness and safety, and obtain a better comprehension of their interactions with cells and tissues in the body.

NGS Applications

Whole Genome Sequencing

By comprehensively analyzing genetic variations, whole genome sequencing enables drug discovery researchers to identify new disease-causing mutations and biological targets, expediting the development of novel precision medicines.

Whole Exome Sequencing

Whole exome sequencing allows drug discovery researchers to detect disease-causing mutations and potential therapeutic targets by rapidly studying the protein-coding sections of DNA, boosting the development of revolutionary medicines.

RNA Sequencing

RNA sequencing enables drug discovery researchers to locate novel therapeutic targets and disease-associated biomarkers by evaluating gene expression levels, offering crucial genomic insights to hasten the creation of cutting-edge medications.

Mass Spectrometry Applications

Proteomics

Mass spectrometry proteomics services allow drug development researchers to validate therapeutic targets, test drug candidates, and establish protein biomarkers for measuring drug efficacy and toxicity by identifying and quantifying proteins involved in disease pathways.

Biologics Characterization

Mass spectrometry biologics characterization services assist drug discovery researchers in maximizing lead compound selection and developability assessments during preclinical development by extensively examining the structure, changes, and purity of protein-based therapeutic candidates.

Metabolomics

Mass spectrometry metabolomics services give drug discovery researchers the ability to assess drug efficacy, toxicity, and mechanisms of action during preclinical development by profiling drug-induced metabolic alterations in biological systems.

Multi-omics

By combining proteomics, metabolomics, and genomics data to provide a comprehensive view of drug response, mass spectrometry multi-omics services enable drug discovery researchers to identify mechanisms of action, biomarkers, and potential toxicity targets during preclinical drug screening and development.

If you want more information？
Consult us now!